GHRP-6: Growth Hormone Releasing Peptide Guide 2026

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It belongs to the growth hormone secretagogue (GHS) family — compounds that stimulate endogenous growth hormone release from the anterior pituitary gland. Developed in the 1980s by Cyril Bowers and colleagues, GHRP-6 was one of the first synthetic peptides shown to reliably stimulate GH secretion.

GHRP-6 acts primarily through the growth hormone secretagogue receptor (GHS-R1a), which was later identified as the ghrelin receptor. This receptor is expressed on somatotroph cells in the anterior pituitary and in the hypothalamic arcuate nucleus, allowing GHRP-6 to stimulate GH release through both direct pituitary action and hypothalamic signalling.

Unlike growth hormone releasing hormone (GHRH), which acts through a separate receptor to modulate GH gene transcription and release, GHRP-6 amplifies GH secretion through a distinct, complementary pathway. This mechanistic independence means GHRP-6 and GHRH analogues produce synergistic GH responses when co-administered — a principle widely exploited in GH-axis research.

GHRP-6 remains one of the most extensively studied GH secretagogues, with hundreds of publications documenting its pharmacology, efficacy, and safety profile across preclinical and clinical models.

GHRP-6's mechanism of action involves multiple levels of the hypothalamic-pituitary GH axis. At the pituitary level, GHRP-6 binds GHS-R1a on somatotroph cells, triggering a phospholipase C/IP3-mediated calcium influx that promotes GH vesicle exocytosis. This is distinct from GHRH's cAMP-dependent signalling, explaining the synergistic interaction between the two pathways.

At the hypothalamic level, GHRP-6 stimulates GHRH-producing neurons in the arcuate nucleus while simultaneously suppressing somatostatin release from the periventricular nucleus. This dual hypothalamic action creates a permissive environment for GH release — increasing the stimulatory signal while removing the inhibitory brake.

Research indicates that GHRP-6 produces a robust, pulsatile GH response that mimics the natural physiological pattern. A single subcutaneous injection typically produces peak GH levels within 15-30 minutes, returning to baseline within 2-3 hours. This pulsatile pattern is considered more physiological than continuous GH elevation and preserves negative feedback mechanisms.

GHRP-6 also stimulates the release of other pituitary hormones to a lesser degree. Studies document modest increases in ACTH, cortisol, and prolactin following GHRP-6 administration, though these effects are considerably smaller than the GH response and generally transient. The ghrelin-mimetic properties of GHRP-6 also increase appetite through hypothalamic NPY/AgRP neuron activation — a notable effect that distinguishes it from more selective secretagogues like ipamorelin.

GHRP-6 has been used extensively in GH-axis research across multiple domains. In diagnostic endocrinology, GHRP-6 stimulation tests are used to assess GH reserve, diagnose GH deficiency, and evaluate pituitary function. The GHRP-6 stimulation test is considered more reliable than insulin tolerance testing in certain populations and has been adopted by multiple endocrine societies as a validated diagnostic tool.

In aging research, GHRP-6 has been studied as a means of restoring the age-related decline in GH secretion known as somatopause. GH pulse amplitude decreases approximately 14% per decade after age 30, contributing to changes in body composition, bone density, and metabolic function. Research suggests that GHRP-6 can partially restore youthful GH pulsatility in elderly subjects without exceeding physiological GH ranges.

Body composition research has demonstrated that GHRP-6-stimulated GH release promotes lipolysis, nitrogen retention, and lean mass preservation. Unlike exogenous GH administration, GHRP-6 maintains the pulsatile release pattern and preserves pituitary feedback mechanisms, potentially offering a more physiological approach to GH-axis modulation.

Gastrointestinal research has revealed that GHRP-6 exerts cytoprotective effects on gastric mucosa independent of its GH-releasing action. Studies indicate GHRP-6 protects against ethanol-induced and NSAID-induced gastric lesions, likely through mechanisms involving nitric oxide and prostaglandin pathways.

- Full Name: Growth Hormone Releasing Peptide-6 - Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 - Molecular Formula: C₄₆H₅₆N₁₂O₆ - Molecular Weight: 873.01 g/mol - Classification: Synthetic hexapeptide GH secretagogue - Receptor Target: GHS-R1a (ghrelin receptor) - Half-life: Approximately 15-60 minutes - Peak GH Response: 15-30 minutes post-injection

The inclusion of two D-amino acids (D-Trp and D-Phe) in the GHRP-6 sequence confers resistance to proteolytic degradation and is essential for receptor binding activity. The C-terminal amidation further enhances metabolic stability.

Peptides Pharma GHRP-6 vials are manufactured to >99% HPLC purity in GMP-certified facilities. Each vial includes full Certificate of Analysis with independent mass spectrometry confirmation.

The GH secretagogue class includes several peptides with overlapping but distinct pharmacological profiles. Understanding these differences is essential for research protocol design.

GHRP-6 vs Ipamorelin: Ipamorelin is the most selective GHS-R1a agonist, producing GH release with minimal effects on ACTH, cortisol, or prolactin. GHRP-6 is less selective, producing greater appetite stimulation and modest cortisol elevation alongside its GH response. Researchers prioritising pure GH release often prefer ipamorelin, while those studying ghrelin-axis physiology or appetite regulation may prefer GHRP-6.

GHRP-6 vs GHRP-2: GHRP-2 is considered approximately twice as potent as GHRP-6 on a microgram basis but shares similar non-selectivity regarding ACTH and cortisol co-release. GHRP-2 produces less appetite stimulation than GHRP-6.

GHRP-6 vs Hexarelin: Hexarelin is the most potent GH secretagogue by weight but shows the most rapid tachyphylaxis (receptor desensitisation with repeated use). GHRP-6 maintains its efficacy better over extended protocols, making it more suitable for chronic research designs.

GHRP-6 + CJC-1295 Synergy: Combining GHRP-6 with the GHRH analogue CJC-1295 produces GH responses that are 2-3 times greater than either compound alone. This synergy is well-documented and widely utilised in GH-axis research. Buy GHRP-6 and CJC-1295 research vials from Peptides Pharma for synergistic protocols.

Published research protocols for GHRP-6 typically employ 1-2 mcg/kg body weight per injection, administered 2-3 times daily via subcutaneous injection. For a 75 kg individual, this corresponds to approximately 75-150 mcg per injection.

Timing of administration significantly impacts GH response magnitude. GHRP-6 is most effective when administered in a fasted state, as elevated blood glucose and free fatty acids attenuate GH secretion. Pre-meal dosing (30 minutes before food) and bedtime dosing are the most commonly cited protocols in the literature.

For synergistic protocols combining GHRP-6 with CJC-1295, published research typically uses equimolar or equimass doses of both peptides administered simultaneously. The combined injection produces a rapid, high-amplitude GH pulse followed by sustained elevation — replicating the ideal physiological pattern.

Research protocol duration varies by objective. Short-term GH-axis characterisation studies may last 1-4 weeks, while body composition and aging research protocols typically extend to 8-16 weeks. Unlike hexarelin, GHRP-6 demonstrates relatively modest tachyphylaxis, maintaining meaningful GH responses throughout extended protocols when appropriate dosing intervals are maintained.

Peptides Pharma GHRP-6 vials are available for research with worldwide delivery. All GHRP-6 UK orders ship with cold-chain packaging and full Certificate of Analysis.